FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383218385> ?p ?o ?g. }

• W4383218385 abstract "The average life expectancy post-left ventricular assist device (LVAD) implantation has significantly increased in recent years. Impaired cellular immunity post-LVAD implantation has been suggested. It is not clear if a prolonged duration of LVAD support will lead to an increase in infections and possibly cause opportunistic infections, as seen in immunocompromised patients. Methods: We retrospectively reviewed all the patients who underwent new continuous-flow (C-F) LVAD implantation between January 1, 2013, and December 31, 2014, at the University of Nebraska Medical Center. Patients were followed until heart transplant, LVAD explantation, death, or December 31, 2017. We defined LVAD infections as per the International Society of Heart and Lung Transplantation (ISHLT) definition: VAD-specific, VAD-related, and non-VAD infections. The primary outcome was to calculate the incidence of LVAD infections per 1000 days of LVAD support. Secondary outcomes were to assess the cause of death and the effect of bloodstream infections on LVAD thrombosis, stroke, and death. Results: During the study period, a total of 94 patients underwent a C-F LVAD implantation. Five patients were lost in follow-up; 89 patients were included in the study. The mean age at LVAD implantation was 54 (SD+15) years. Out of 89 patients, 67 (75%) were men, and 53/89 (71%) received LVAD as destination therapy (DT). At the time of LVAD implantation, 34/89 (38%) patients had ITERMACS (interagency registry for mechanically assisted circulatory support) score 1 (cardiogenic shock). The median duration of LVAD support was 387+493 days, with an interquartile range of 140 to 1083 days. The incidence rate of infections post-LVAD implantation decreased from 3.2 /1000 LVAD days (95% confidence interval [CI] 2.54-4.03) during the first year of LVAD support to 0.78/1000 LVAD days (95% CI, 0.38-1.65) during the following third year of LVAD support. Similarly, the incidence of VAD-specific infections in the first year post-LVAD implantation versus the third-year post LVAD implantation decreased from 0.83/1000 LVAD days (95% CI, 0.53-1.30) to 0.33/1000 LVAD days (95% CI, 0.10-1.04). On univariate survival analysis, an increased risk of death was associated with a one-year increase in age at LVAD implantation (hazard ratio (HR) 1.05 (95% CI, 1.01-1.09), p=0.01), the presence of infection within 30 days before LVAD implantation (HR 2.44 (95% CI, 1.09-5.48), p=0.03), underlying ischemic cardiomyopathy (HR 2.96 (95% CI, 1.28-6.80), p=0.01), and lower ITERMACS profile HR 3.64 (95% CI, 1.09-12.13, p=0.04). Bloodstream infections (BSIs) were not associated with an increased risk of death (HR 1.63 (95% CI, 0.56-4.80, p=0.37). Univariate survival analysis for poor outcomes (LVAD thrombosis, stroke, or death) showed BSIs increased the risk of having a poor outcome (HR 2.39 (95% CI, 1.02-5.57), p=0.04). Conclusions: The incidence rate of post-LVAD infections decreased significantly over time. LVAD implantation may not be contributing to immune suppression as previously suggested. In our study, BSIs were found to have a significantly increased hazard ratio for a poor outcome post-LVAD implantation." @default.
• W4383218385 created "2023-07-06" @default.
• W4383218385 creator A5001704024 @default.
• W4383218385 creator A5057455263 @default.
• W4383218385 date "2023-07-05" @default.
• W4383218385 modified "2023-10-14" @default.
• W4383218385 title "Risk of Infections With Long-Term Left Ventricular Assist Device Support" @default.
• W4383218385 cites W1492950536 @default.
• W4383218385 cites W1984169032 @default.
• W4383218385 cites W1997836043 @default.
• W4383218385 cites W2004436669 @default.
• W4383218385 cites W2014315092 @default.
• W4383218385 cites W2063887836 @default.
• W4383218385 cites W2083243211 @default.
• W4383218385 cites W2083896869 @default.
• W4383218385 cites W2196906371 @default.
• W4383218385 cites W2335953978 @default.
• W4383218385 cites W2547341976 @default.
• W4383218385 cites W2588030598 @default.
• W4383218385 cites W2610602137 @default.
• W4383218385 cites W2913417252 @default.
• W4383218385 cites W3046795109 @default.
• W4383218385 cites W3137859093 @default.
• W4383218385 doi "https://doi.org/10.7759/cureus.41412" @default.
• W4383218385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37546149" @default.
• W4383218385 hasPublicationYear "2023" @default.
• W4383218385 type Work @default.
• W4383218385 citedByCount "0" @default.
• W4383218385 crossrefType "journal-article" @default.
• W4383218385 hasAuthorship W4383218385A5001704024 @default.
• W4383218385 hasAuthorship W4383218385A5057455263 @default.
• W4383218385 hasBestOaLocation W43832183851 @default.
• W4383218385 hasConcept C119060515 @default.
• W4383218385 hasConcept C120665830 @default.
• W4383218385 hasConcept C121332964 @default.
• W4383218385 hasConcept C126322002 @default.
• W4383218385 hasConcept C127413603 @default.
• W4383218385 hasConcept C141071460 @default.
• W4383218385 hasConcept C164705383 @default.
• W4383218385 hasConcept C2776850375 @default.
• W4383218385 hasConcept C2778198053 @default.
• W4383218385 hasConcept C2778774980 @default.
• W4383218385 hasConcept C2778849806 @default.
• W4383218385 hasConcept C2779326848 @default.
• W4383218385 hasConcept C2780645631 @default.
• W4383218385 hasConcept C2911091166 @default.
• W4383218385 hasConcept C500558357 @default.
• W4383218385 hasConcept C61511704 @default.
• W4383218385 hasConcept C71924100 @default.
• W4383218385 hasConcept C78519656 @default.
• W4383218385 hasConceptScore W4383218385C119060515 @default.
• W4383218385 hasConceptScore W4383218385C120665830 @default.
• W4383218385 hasConceptScore W4383218385C121332964 @default.
• W4383218385 hasConceptScore W4383218385C126322002 @default.
• W4383218385 hasConceptScore W4383218385C127413603 @default.
• W4383218385 hasConceptScore W4383218385C141071460 @default.
• W4383218385 hasConceptScore W4383218385C164705383 @default.
• W4383218385 hasConceptScore W4383218385C2776850375 @default.
• W4383218385 hasConceptScore W4383218385C2778198053 @default.
• W4383218385 hasConceptScore W4383218385C2778774980 @default.
• W4383218385 hasConceptScore W4383218385C2778849806 @default.
• W4383218385 hasConceptScore W4383218385C2779326848 @default.
• W4383218385 hasConceptScore W4383218385C2780645631 @default.
• W4383218385 hasConceptScore W4383218385C2911091166 @default.
• W4383218385 hasConceptScore W4383218385C500558357 @default.
• W4383218385 hasConceptScore W4383218385C61511704 @default.
• W4383218385 hasConceptScore W4383218385C71924100 @default.
• W4383218385 hasConceptScore W4383218385C78519656 @default.
• W4383218385 hasLocation W43832183851 @default.
• W4383218385 hasLocation W43832183852 @default.
• W4383218385 hasLocation W43832183853 @default.
• W4383218385 hasOpenAccess W4383218385 @default.
• W4383218385 hasPrimaryLocation W43832183851 @default.
• W4383218385 hasRelatedWork W1971244460 @default.
• W4383218385 hasRelatedWork W2040160165 @default.
• W4383218385 hasRelatedWork W2081911454 @default.
• W4383218385 hasRelatedWork W2143015101 @default.
• W4383218385 hasRelatedWork W2412475215 @default.
• W4383218385 hasRelatedWork W2478999338 @default.
• W4383218385 hasRelatedWork W2774859156 @default.
• W4383218385 hasRelatedWork W2920043851 @default.
• W4383218385 hasRelatedWork W2967632883 @default.
• W4383218385 hasRelatedWork W4365505301 @default.
• W4383218385 isParatext "false" @default.
• W4383218385 isRetracted "false" @default.
• W4383218385 workType "article" @default.